ClinicalTrials.gg

Program

resmetirom

Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.

Furthest: phase 4, since Aug 25, 202622 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Madrigal Pharmaceuticals207 open or runningphase 4since Aug 25, 2026Jun 2, 2011Dec 2026phase 3 · NCT05500222
Nabiqasim Industries (Pvt)11 open or runningphase 4since Nov 18, 2025Nov 18, 2025none ahead
Sagimet Biosciences10 open or runningphase 1since Oct 8, 2025Oct 8, 2025none ahead

Also a collaborator on its studies: celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Jun 2, 2011.

  1. Jan 22, 2018Phase 1 study in HealthyMadrigal Pharmaceuticals · NCT03413124 · 16 enrolled · United States
  2. Mar 26, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT03900429 · 1,759 enrolled · United States, Australia, Austria and more
  3. Dec 11, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04197479 · 1,343 enrolled · United States, Puerto Rico
  4. Oct 22, 2020Phase 1 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04643795 · 87 enrolled · United States
  5. Dec 10, 20202 phase 1 studies in HealthyMadrigal Pharmaceuticals · NCT04671069, NCT04671056
  6. Jun 18, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219 · 810 enrolled · United States, Puerto Rico
  7. Aug 11, 2022Phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222 · 845 enrolled · United States, Belgium, Canada and more
  8. Apr 30, 2024Phase 1 study in Renal InsufficiencyMadrigal Pharmaceuticals · NCT06397872 · 28 enrolled · United States
  9. Oct 8, 2025Sagimet Biosciences's first study: phase 1 study in HealthyNew to Sagimet BiosciencesSagimet Biosciences · NCT07216313 · 40 enrolled · United States
  10. Nov 18, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT07249788 · 165 planned · Pakistan
  11. Jan 7, 2026Phase 2 study in FibrosisMadrigal Pharmaceuticals · NCT07335601 · 120 planned · United States, Canada
  12. Aug 10, 2026Phase 2 study in Liver DiseasesMadrigal Pharmaceuticals · NCT07763015 · 61 planned · United States
  13. Aug 25, 2026Phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191 · 150 planned · United States
  14. Aug 25, 2026Phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758 · 90 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222
  2. Mar 2027Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219
  3. Nov 2027Primary completion: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191
  4. Nov 2027Primary completion: phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758

TargetBeta

THRB →read by rule
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule

Other programs on THRB

ProgramCompanyFurthest phaseStudies
KYLO-0603Sino Biopharmaceuticalphase 22
CG-0416rulehongkong-curegene-innovation-co-limitedphase 11
KPC000154rulekunming-pharmaceuticals-incphase 11

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07848191MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States4RecruitingMadrigal PharmaceuticalsNov 2027150
NCT07830758MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States1RecruitingMadrigal PharmaceuticalsNov 202790
NCT07763015Liver Diseases · United States2RecruitingMadrigal PharmaceuticalsJul 202961
NCT07335601Fibrosis · United States, Canada2RecruitingMadrigal PharmaceuticalsAug 2028120
NCT07249788MASH - Metabolic Dysfunction-Associated Steatohepatitis · Pakistan4RecruitingNabiqasim Industries (Pvt)Oct 16, 2026165
NCT07216313Healthy · United States1CompletedSagimet BiosciencesOct 20, 202540
NCT06397872Renal Insufficiency · United States1CompletedMadrigal PharmaceuticalsSep 16, 202428
NCT05500222Liver Cirrhosis · United States, Belgium, Canada and more3Active, not recruitingMadrigal PharmaceuticalsDec 2026845
NCT04951219Non-alcoholic Fatty Liver Disease · United States, Puerto Rico3Active, not recruitingMadrigal PharmaceuticalsMar 2027810
NCT04671069Healthy · United States1CompletedMadrigal PharmaceuticalsAug 30, 201920
NCT04671056Healthy · United States1CompletedMadrigal PharmaceuticalsDec 11, 201816
NCT04643795Non-alcoholic Fatty Liver Disease · United States1CompletedMadrigal PharmaceuticalsAug 4, 202187
NCT04197479Non-alcoholic Fatty Liver Disease · United States, Puerto Rico3CompletedMadrigal PharmaceuticalsJan 6, 20231,343
NCT03900429Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more3Active, not recruitingMadrigal PharmaceuticalsJan 20281,759
NCT03413124Healthy · United States1CompletedMadrigal PharmaceuticalsFeb 17, 201816
NCT03220165Healthy · United States1CompletedMadrigal PharmaceuticalsSep 3, 20178
NCT03038022Heterozygous Familial Hypercholesterolemia · Denmark, Netherlands, Norway2CompletedMadrigal PharmaceuticalsJan 15, 2018116
NCT02912260Non-alcoholic Fatty Liver Disease · United States2CompletedMadrigal PharmaceuticalsOct 25, 2017125
NCT02749578Healthy · United States1CompletedMadrigal PharmaceuticalsMay 201614
NCT02542969Healthy · United States1CompletedMadrigal PharmaceuticalsOct 201525
NCT01519531Drug Safety · United States1CompletedMadrigal PharmaceuticalsNov 201248
NCT01367873Drug Safety · United States1CompletedMadrigal PharmaceuticalsOct 201172

How it is read

Names in the registry

  • “Resmetirom”, 9 entries
  • “MGL-3196”, 8 entries
  • “VIA-3196”, 2 entries
  • “Rezdiffra”, 1 entry
  • “MGL-3196 (resmetirom)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.